Venture Round - CellCentric

Venture Round - CellCentric

Investment Firm

Overview

CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.

Announced Date

Jan 26, 2022

Funding Type

Series Unknown

Highlights

Location

Europe

Social

Investor Lead

BrightEdge Fund

BrightEdge Fund

BrightEdge Fund is a early_stage_venture firm.

Participant Investors

1

Investor Name
Participant InvestorBrightEdge Fund

Round Details and Background

CellCentric raised an undisclosed amount on 2022-01-26 in Venture Round

CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.

Company Funding History

18

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jul 11, 2023
Corporate Round - CellCentric
1-25.0M
Jul 24, 2024
Venture Round - CellCentric
1-35.0M
Jun 01, 2017
Venture Round - CellCentric
1-undefined
Jun 25, 2013
Venture Round - CellCentric
4-6.6M

Recent Activity

There is no recent news or activity for this profile.